Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.
1. A method for the treatment of a non-alcoholic fatty liver disease in a subject in need thereof, comprising administering to the subject a compound selected from 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one or a pharmaceutically acceptable salt or a stereoisomer thereof.
2. The method according to claim 1 , wherein the compound is orally administered.
3. The method of claim 1 , wherein the compound is administered as an injectable suspension, a gel, a oil, a pill, a suppository, a powder, a gel cap, a capsule, an aerosol, a galenic form, a prolonged release formulation or a slow release form.
4. The method of claim 1 , wherein the compound is administered in combination with metformin, insulin, a thiazolidinedione, a glitazone, or a statin.
5. The method of claim 1 , comprising administering a pharmaceutical composition comprising 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one or a pharmaceutically acceptable salt or a stereoisomer thereof.
6. The method of claim 5 , wherein said composition is formulated in the form of an injectable suspension, a gel, an oil, a pill, a suppository, a powder, a gel cap, a capsule, an aerosol, a galenic form, a prolonged release formulation or a slow release form.
7. The method of claim 5 , wherein said composition is in an oral form.
8. The method of claim 1 , wherein the non-alcoholic fatty liver disease is non-alcoholic steatohepatitis.
9. The method of claim 5 , wherein the non-alcoholic fatty liver disease is non-alcoholic steatohepatitis.
10. The method of claim 1 , wherein said treatment delays progression of said non-alcoholic fatty liver disease.
11. The method of claim 5 , wherein said treatment delays progression of said non-alcoholic fatty liver disease.